Avadel Pharmaceuticals plc (AVDL) Financial Statements (2023 and earlier)

Company Profile

Business Address BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
DUBLIN, 15
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments96,499157,22173,19964,15812,67594,075
Cash and cash equivalents73,98150,70871,7229,7749,32516,564
Short-term investments22,518106,5131,47754,3843,35077,511
Receivables6929,09718,9569,86813,62916,509
Inventory, net of allowances, customer advances and progress billings   3,5704,7706,157
Inventory   3,5704,7706,157
Prepaid expense1,5233,1791,0182,1162,1457,106
Other current assets228271457107225 
Other undisclosed current assets2,5242,722169,8242,56191,407128
Total current assets:100,843192,490263,45482,380124,851123,975
Noncurrent Assets
Operating lease, right-of-use asset1,7132,6522,604 
Property, plant and equipment8392853595441,9113,001
Intangible assets, net (including goodwill)16,83616,83616,83619,30420,120110,780
Goodwill16,83616,83616,83618,49118,49118,491
Intangible assets, net (excluding goodwill)    8131,62992,289
Other noncurrent assets11,32233,77724,93939,27436,14610,249
Other undisclosed noncurrent assets1,2321,2253,4459,9347,2725,272
Total noncurrent assets:31,94254,77548,18369,05665,449129,302
TOTAL ASSETS:132,785247,265311,637151,436190,300253,277
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15,22414,8309,43525,91025,27158,817
Taxes payable   73414
Accounts payable7,8907,6792,9346,1003,5037,477
Accrued liabilities7,3347,1516,50119,81021,69550,926
Debt37,668   106111
Deferred revenue and credits2,007
Due to related parties    5,5549,43925,007
Contract with customer, liability114
Other liabilities1,9415,2705,2003,8753,453597
Other undisclosed current liabilities960900474645  
Total current liabilities:55,79321,00015,10935,98438,38386,539
Noncurrent Liabilities
Long-term debt and lease obligation 91,614144,104130,050121,686115,734156
Long-term debt, excluding current maturities 91,614142,397128,210121,686115,734156
Liabilities, other than long-term debt6,5233,9174,21220,64633,40381,002
Due to related parties    11,77319,40173,918
Other liabilities5,7433,9174,2128,87314,0027,084
Operating lease, liability7801,7071,840 
Other undisclosed noncurrent liabilities    2,319  
Total noncurrent liabilities:98,137148,021134,262144,651149,13781,158
Total liabilities:153,930169,021149,371180,635187,520167,697
Equity
Equity, attributable to parent(21,145)78,244162,266(29,199)2,78085,580
Preferred stock555   
Common stock628586583429427414
Treasury stock, value    (49,998)(49,998)(22,361)
Additional paid in capital589,783549,349566,916434,391433,756393,478
Accumulated other comprehensive loss(26,341)(23,940)(21,051)(22,806)(23,416)(23,266)
Accumulated deficit(585,220)(447,756)(384,187)(391,215)(357,989)(262,685)
Total equity:(21,145)78,244162,266(29,199)2,78085,580
TOTAL LIABILITIES AND EQUITY:132,785247,265311,637151,436190,300253,277

Income Statement (P&L) ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues11611022,33459,215103,269173,245
Revenue, net173,245
Sublease income 116110336 
Cost of revenue(3,345) (6,105)(17,065)(25,151)(22,502)
Cost of goods and services sold  (5,742)(12,125)(17,516)(16,301)
Gross profit:(3,229)11016,22942,15078,118150,743
Operating expenses(95,216)(85,599)(10,414)(66,262)(183,044)(61,238)
Other undisclosed operating loss(116)(57)    
Operating income (loss):(98,561)(85,546)5,815(24,112)(104,926)89,505
Nonoperating income (expense)(536)2,126(1,267)(1,987)2,3514,207
Investment income, nonoperating(536)2,126(832)(1,609)4522,850
Loss, foreign currency transaction, before tax      (714)
Other nonoperating income (expense)   (435)(378)1,8992,071
Interest and debt expense(12,342)(9,942)(12,994)(12,483)(10,622)(1,052)
Other undisclosed income from continuing operations before equity method investments, income taxes   3,364   
Income (loss) from continuing operations before equity method investments, income taxes:(111,439)(93,362)(5,082)(38,582)(113,197)92,660
Other undisclosed income (loss) from continuing operations before income taxes 217    
Income (loss) from continuing operations before income taxes:(111,439)(93,145)(5,082)(38,582)(113,197)92,660
Income tax expense (benefit)(26,025)15,81612,1105,35617,893(24,389)
Income (loss) from continuing operations:(137,464)(77,329)7,028(33,226)(95,304)68,271
Income (loss) before gain (loss) on sale of properties:(77,329)7,028(33,226)(95,304)68,271
Net income (loss) available to common stockholders, diluted:(137,464)(77,329)7,028(33,226)(95,304)68,271

Comprehensive Income ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(137,464)(77,329)7,028(33,226)(95,304)68,271
Other comprehensive loss      
Comprehensive income (loss):(137,464)(77,329)7,028(33,226)(95,304)68,271
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2,401)(2,889)1,755610(150)299
Comprehensive income (loss), net of tax, attributable to parent:(139,865)(80,218)8,783(32,616)(95,454)68,570

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: